The article discusses the strategy of Dilip Shantilal Shanghvi, founder of Sun Pharmaceuticals in Mumbai, India in response to the problems of its U.S.-based subsidiary Caraco. Reportedly, the Food and Drug Administration (FDA) issued a warning letter to Caraco regarding quality control issues in October 31, 2008. In June 25, 2009, the FDA seized drugs from Caraco's facility in Detroit, Michigan for violating good manufacturing practices (GMP) and is facing two class-action lawsuits.